Filing Flows › Atara Biotherapeutics (ATRA) › Q4 2025
Atara Biotherapeutics (ATRA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 16, 2026
Atara Biotherapeutics (ATRA) reported revenue of $1.6M for the fourth quarter 2025 (Q4 2025), -95% from a year earlier and -54% from the quarter before. Operating margin was -160.7%, net loss $3.4M (213.5% of revenue).
Atara Biotherapeutics, Q4 2025: revenue $1.6M (-95% year over year), operating margin -160.7%, net loss $3.4M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | -54% | -95% |
| Operating profit | −$2.6M | — | — |
| Net earnings | −$3.4M | — | — |
| Operating cash flow | −$5.7M | — | — |
What changed
Revenue was $1.6M in Q4 2025, down 95% year over year and down 54% from the previous quarter.
Operating costs exceeded revenue by $2.6M, an operating margin of -160.7%. Total costs fell 91% while revenue fell 95%. The quarter ended with a net loss of $3.4M, narrower than the previous quarter's $4.3M loss.
Operating cash flow was −$5.7M. Non-cash charges added back $49K of depreciation and amortization and $1.5M of share-based compensation. Working capital and other items used $3.9M.
Questions
What was Atara Biotherapeutics' revenue in the fourth quarter 2025?
Atara Biotherapeutics (ATRA) reported revenue of $1.6M for the fourth quarter 2025 (Q4 2025), -95% from a year earlier and -54% from the quarter before.
Was Atara Biotherapeutics profitable in the fourth quarter 2025?
Operating loss was $2.6M (-160.7% of revenue) and net loss $3.4M.